세계의 의약품 CDMO 시장 보고서(2025년)
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Global Market Report 2025
상품코드 : 1811002
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 의약품 CDMO 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년까지 CAGR 10.7%로 확대되어 821억 5,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 생물제제와 첨단요법 급증, 맞춤형 의료 확대, 지속적인 제조 중시, 아웃소싱에 대한 규제 장려, 의약품 제조에서 디지털화와 자동화의 채용 증가에 기인한다고 생각됩니다. 이 기간에 예상되는 주요 동향으로는 연속 제조 기술의 발전, 의약품 개발 프로세스에서의 AI와 머신러닝의 통합, 고활성 의약품원료(HPAPI) 취급 능력의 확대, 생물 제제와 복잡한 주사제 제형의 채용 증가, 지속 가능하고 친환경 제조 프랙티스에 대한 주목 증가 등이 있습니다.

의약품 개발 및 제조 활동의 활성화는 의약품 CDMO 시장의 성장을 견인할 것으로 예측됩니다. 의약품 개발 및 제조란 제약기업이나 바이오의약품 기업이 새로운 치료를 연구, 개발 및 제조하는 대처를 말합니다. 이러한 활동은 신규하고 효과적인 치료에 대한 세계적인 수요가 증가함에 따라 활발해지고 있으며, 기업은 개발 파이프라인을 확대하고 생산 스케줄을 가속화하도록 촉구하고 있습니다. CDMO는 제형의 제형과 최적화, 안정성 검사 수행, 규정 준수 보장, 스케일업 및 생산 관리를 통해 이 프로세스를 지원합니다. 이를 통해 더 빠르고 비용 효율적인 제품 출시가 가능합니다. 예를 들어, 벨기에에 본부를 둔 제약산업의 산업단체인 유럽 제약단체연합회(EFPIA)는 2023년 6월, 유럽의 의약품 생산액이 2022년의 3,939억 달러(3,633억 유로)에서 2023년에는 4,228억 달러(3,90달러)로 보고했습니다. 따라서 의약품 개발 및 제조 확대는 제형용 CDMO 시장의 성장에 기여하고 있습니다.

의약품 CDMO 시장의 주요 기업은 복잡한 생물학적 치료의 약물 안정성을 향상시키고 전달 일정을 단축하기 위해 첨단 생물 제형 플랫폼의 개발에 주력하고 있습니다. 이러한 생물 제형 플랫폼은 pH 수준, 부형제, 전달 메커니즘 등 다양한 제형 파라미터를 최적화하고 생물 제제의 수명주기를 통해 안정성, 안전성, 생체이용률을 향상시키는 전문 시스템입니다. 예를 들어, 2025년 6월 중국의 연구개발 및 제조 수탁기업인 WuXi Biologics는 차세대 고농도 제형 플랫폼인 WuXiHigh 2.0을 발표했습니다. 이 플랫폼은 FDA의 승인 한계인 200mg/mL를 초과하는 최대 230mg/mL의 단백질 농도의 생물 제제를 가능하게 합니다. 또한 독자적인 부형제 블렌드와 고성능 스크리닝을 통해 점도를 최대 90%까지 줄일 수 있습니다. WuXiHigh 2.0은 고농도 생물 제제의 주요 과제인 응집과 점도를 해결하여 임상 및 상업 단계를 통해 주사 효율, 환자 규정 준수 및 제조 성능을 향상시킵니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

A pharmaceutical contract development and manufacturing organization (CDMO) for formulations is a company that offers outsourced services to support the development and production of drug formulations on behalf of pharmaceutical companies. These services typically include formulation development, analytical testing, production of clinical trial materials, and large-scale commercial manufacturing.

The primary types of dosage forms provided by pharmaceutical CDMOs for formulations include oral solids, oral liquids, injectables, topicals, inhalation products, transdermals and patches, among others. Oral solid dosage forms are medications administered orally and designed to deliver the active drug through the digestive system. These dosage forms are applied across various therapeutic areas such as oncology, cardiology, central nervous system disorders, gastroenterology, infectious diseases, and endocrinology. The services are utilized by a range of end users, including pharmaceutical companies, biopharmaceutical firms, and other related organizations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market statistics, including the pharmaceutical contract development and manufacturing organizations (CDMO) for formulations industry global market size, regional shares, competitors with the pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market share, detailed pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market segments, market trends, opportunities, and any further data you may need to thrive in the pharmaceutical contract development and manufacturing organizations (CDMO) for formulations industry. This pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market size has grown rapidly in recent years. It will grow from $49.32 billion in 2024 to $54.73 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth during the historic period can be attributed to the rise in pharmaceutical outsourcing, increasing complexity of drug formulations, cost-reduction strategies adopted by pharmaceutical companies, growing demand for generics and biosimilars, and the expansion of small and mid-sized pharmaceutical firms.

The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market size is expected to see rapid growth in the next few years. It will grow to $82.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the surge in biologics and advanced therapies, the expansion of personalized medicine, increasing emphasis on continuous manufacturing, regulatory encouragement for outsourcing, and the rising adoption of digitalization and automation in pharmaceutical production. Key trends anticipated during this period include the advancement of continuous manufacturing technologies, integration of AI and machine learning in drug development processes, expansion of high-potency API (HPAPI) handling capabilities, increased adoption of biologics and complex injectable formulations, and a growing focus on sustainable and environmentally friendly manufacturing practices.

The increasing activities in drug development and manufacturing are expected to drive the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market. Drug development and manufacturing refer to the efforts by pharmaceutical and biopharmaceutical companies to research, develop, and produce new therapeutic drugs. These activities are rising due to the growing global demand for novel and effective treatments, which encourages companies to broaden their development pipelines and accelerate production timelines. CDMOs support this process by formulating and optimizing dosage forms, conducting stability testing, ensuring regulatory compliance, and managing scale-up and production. This enables quicker and more cost-effective product launches. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based pharmaceutical industry trade group, reported that pharmaceutical production in Europe reached $422.8 billion (€390 billion) in 2023, up from $393.9 billion (€363.3 billion) in 2022. Therefore, the expansion of drug development and manufacturing is contributing to the growth of the CDMO market for formulations.

Leading companies in the pharmaceutical CDMO for formulations market are focusing on the development of advanced biologic formulation platforms to improve drug stability and speed up delivery timelines for complex biologic therapies. These biologic formulation platforms are specialized systems that optimize various formulation parameters-such as pH levels, excipients, and delivery mechanisms-to enhance the stability, safety, and bioavailability of biologic drugs throughout their lifecycle. For example, in June 2025, WuXi Biologics, a China-based contract research, development, and manufacturing company, introduced WuXiHigh 2.0, a next-generation high-concentration formulation platform. This platform allows biologic formulations with protein concentrations up to 230 mg/mL, exceeding the FDA-approved limit of 200 mg/mL. It also reduces viscosity by up to 90% through proprietary excipient blends and high-throughput screening. WuXiHigh 2.0 addresses key challenges in high-concentration biologics-such as aggregation and viscosity-while improving injection efficiency, patient compliance, and manufacturing performance throughout the clinical and commercial stages.

In February 2025, Jabil Inc., a US-based provider of engineering, manufacturing, and supply chain services, acquired Pharmaceutics International Inc. (Pii) for an undisclosed amount. This acquisition is intended to enhance Jabil's capabilities in pharmaceutical manufacturing and development by leveraging Pii's expertise in aseptic filling, lyophilization, and oral solid dose production. It strengthens Jabil's position in parenteral drug delivery and broadens its comprehensive support across both clinical and commercial manufacturing. Pharmaceutics International Inc. (Pii) is a US-based CDMO that offers formulation development services for a variety of drug forms, ranging from injectable to oral products.

Major players in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, and Aarti Pharmalabs Limited.

Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in pharmaceutical contract development and manufacturing organization (CDMO) for formulations report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market consists of revenues earned by entities by providing services such as analytical and stability testing, formulation development, process development and scale-up, regulatory support and documentation, and commercial-scale manufacturing and packaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market also includes sales of suppositories, ophthalmic preparations, buccal and sublingual tablets, liposomal formulations, and microneedle patches. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmaceutical contract development and manufacturing organization (cdmo) for formulations market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pharmaceutical contract development and manufacturing organization (cdmo) for formulations ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Characteristics

3. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Trends And Strategies

4. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Growth Analysis And Strategic Analysis Framework

6. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Segmentation

7. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Regional And Country Analysis

8. Asia-Pacific Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

9. China Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

10. India Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

11. Japan Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

12. Australia Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

13. Indonesia Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

14. South Korea Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

15. Western Europe Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

16. UK Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

17. Germany Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

18. France Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

19. Italy Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

20. Spain Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

21. Eastern Europe Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

22. Russia Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

23. North America Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

24. USA Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

25. Canada Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

26. South America Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

27. Brazil Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

28. Middle East Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

29. Africa Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

30. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Competitive Landscape And Company Profiles

31. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Other Major And Innovative Companies

32. Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

34. Recent Developments In The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

35. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기